Pre-“Complete Response” Deficiency Communication Possible For ANDA Sponsors
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA and GPhA nearing agreement that would let generic drug sponsors receive a list of major application deficiencies before the agency issues its “complete response” letter.